Unique ID issued by UMIN | UMIN000011484 |
---|---|
Receipt number | R000013439 |
Scientific Title | Low-energy extracorporeal cardiac shock wave therapy in patients with severe ischemic heart disease |
Date of disclosure of the study information | 2013/09/01 |
Last modified on | 2013/08/14 14:49:22 |
Low-energy extracorporeal cardiac shock wave therapy in patients with severe ischemic heart disease
Shock wave therapy for ischemic heart disease
Low-energy extracorporeal cardiac shock wave therapy in patients with severe ischemic heart disease
Shock wave therapy for ischemic heart disease
Japan |
Angina pectoris
Cardiology |
Others
NO
To evaluate the effectiveness of low-energy extracorporeal cardiac shock wave therapy in patients with severe angina pectoris
Safety,Efficacy
Confirmatory
Frequency in use of nitroglycerin per week.
Evaluated at 3 month after the therapy.
CCS class scores, Exercise tolerance, Myocardial perfusion.
Evaluated at 3 month after the therapy.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment |
Extracorporeal cardiac shock wave therapy (3 times in the first week, 200 shots/spot at about 0.1 mJ/mm2 for 40-70 spots each time)
20 | years-old | <= |
Not applicable |
Male and Female
1) Men and women 20 years of age or older.
2) Patients who have chest pain even under standard medication.
3) Patients with no indication of revascularization (PCI or CABG), or patients in whom eonugh improvement is not expected compared to the risk of revascularization.
4) Canadian Cardiovascular Society (CCS) classification, Class II-IV patients.
5) Evidence of myocardial ischemia with myocardial stress-scintigraphy or stress MRI
1) Patients whose target area cannot be observed with echocardiography.
2) Post-breast augmentation surgery with silicon pad.
3) Patients with prosthetic valve (mechanical valve) in the heart.
4) Q-wave myocardial infarction within 3 months.
5) Non-Q-wave myocardial infarction within 6 weeks.
6) Less than 1 month after the last revascularization (PCI or CABG).
7) Patients with cardiogenic shock or worsening heart failure (who require continuous infusion of cardiovascular agents such as inotropic agents or vasodilators).
8) Intracardiac thrombus.
9) Patients whose clinical status changed after the last coronary angiography.
10) Unstable diabetic retinopathy.
11) Patients who have malignancy or who have undergone surgery because of malignancy within the past five years
5
1st name | |
Middle name | |
Last name | Kazuo Misumi |
chibanishi general hospital
Department of Cardiovascular Medicine
Kanegasaku 107-1,Matsudo,Chiba
047-384-8111
1st name | |
Middle name | |
Last name |
chibanishi general hospital
Department of Cardiovascular Medicine
Kanegasaku 107-1,Matsudo,Chiba
047-384-8111
chibanishi general hospital
chibanishi general hospital
Self funding
NO
千葉西総合病院(千葉県)chibanishi general hospital(Chiba)
2013 | Year | 09 | Month | 01 | Day |
Unpublished
Preinitiation
2013 | Year | 07 | Month | 04 | Day |
2013 | Year | 09 | Month | 01 | Day |
2013 | Year | 08 | Month | 14 | Day |
2013 | Year | 08 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013439